Targeting the Galectin-1/Ras Interaction for Treating Malignant Peripheral Nerve Sheath Tumors

Area of Science:

• Oncology
• Molecular Biology
• Pharmacology

Background:

• Neurofibromatosis type 1 (NF1) is a genetic disorder linked to malignant peripheral nerve sheath tumors (MPNSTs), an aggressive sarcoma with limited treatment options.
• Current MPNST treatments have poor outcomes and high recurrence rates, necessitating novel therapeutic strategies.

Purpose of the Study:

• To investigate the potential of targeting the Galectin-1 (Gal-1) and Ras protein interaction as a new therapeutic approach for MPNSTs.
• To evaluate the efficacy of a novel compound, LLS30, designed to disrupt the Gal-1/Ras interaction in MPNSTs.

Main Methods:

• Utilized molecular docking to identify key residues in the Gal-1/Ras interaction.
• Synthesized and tested LLS30 for its ability to inhibit Gal-1/Ras binding.
• Assessed LLS30's efficacy in vitro (cell viability, apoptosis) and in vivo (MPNST xenografts, metastasis models).
• Performed transcriptome sequencing to analyze LLS30's impact on gene expression and signaling pathways.

Main Results:

• LLS30 successfully disrupted the Gal-1/Ras interaction by binding to key residues, leading to Ras delocalization and suppressed Ras/Erk signaling.
• In vitro studies showed LLS30 significantly inhibited MPNST cell proliferation and induced apoptosis.
• In vivo studies demonstrated LLS30's potent anti-tumor and anti-metastatic effects, improving survival in MPNST models.
• Transcriptome analysis revealed LLS30 downregulates critical oncogenic pathways, including KRAS signaling and epithelial-mesenchymal transition (EMT).

Conclusions:

• Disrupting the Gal-1/Ras interaction via LLS30 offers a promising therapeutic strategy for MPNSTs.
• LLS30 exhibits significant anti-tumor and anti-metastatic activity, warranting further clinical investigation.
• This approach may also be beneficial for other cancers driven by Gal-1 and Ras signaling.